An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans-Reference-Cited by-同舟云学术

An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans

Published:2019-01-16 Issue:475 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kurtz Caroline B.¹^ORCID,Millet Yves A.¹,Puurunen Marja K.¹,Perreault Mylène¹,Charbonneau Mark R.¹,Isabella Vincent M.¹^ORCID,Kotula Jonathan W.¹,Antipov Eugene¹,Dagon Yossi¹,Denney William S.²^ORCID,Wagner David A.³^ORCID,West Kip A.¹^ORCID,Degar Andrew J.²,Brennan Aoife M.¹,Miller Paul F.¹^ORCID

Affiliation:

1. Synlogic Inc., 301 Binney Street, Cambridge, MA 02142, USA.

2. Diversigen Inc., 1 Baylor Plaza, Houston, TX 77030, USA.

3. Metabolic Solutions Inc., 460 Amherst Street, Nashua, NH 03063, USA.

Abstract

An engineered E. coli strain lowers blood ammonia, improves survival in models of hyperammonemia, and demonstrates safety in healthy volunteers.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference90 articles.

1. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation